.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Cantor Fitzgerald
Julphar
Colorcon
Merck
McKinsey
US Army
AstraZeneca
Fuji
Citi

Generated: September 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,563,608 protect, and when does it expire?


Patent ► Subscribe protects VASCEPA and is included in one NDA. There has been one Paragraph IV challenge on Vascepa.

This patent has twenty-two patent family members in fourteen countries.

Summary for Patent: ► Subscribe

Title:Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
Abstract: The present invention relates to methods of reducing triglyceride levels in statin-treated subjects having a triglyceride level of 500 mg/dl to 1500 mg/dl.
Inventor(s): Manku; Mehar (England, GB), Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT)
Assignee: Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:13/417,899
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Amarin Pharms
VASCEPA
icosapent ethyl
CAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
Amarin Pharms
VASCEPA
icosapent ethyl
CAPSULE;ORAL202057-002Feb 16, 2017RXYesNo► Subscribe► Subscribe METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,618,166Methods of treating mixed dyslipidemia► Subscribe
9,056,088Pharmaceutical compositions comprising fatty acids► Subscribe
8,691,871Methods of treating mixed dyslipidemia► Subscribe
8,680,144Methods of treating mixed dyslipidemia► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand624963► Subscribe
Russian Federation2011148363► Subscribe
Russian Federation2489145► Subscribe
Russian Federation2624506► Subscribe
BrazilPI1014405► Subscribe
Canada2759176► Subscribe
China102413825► Subscribe
Russian Federation2013106526► Subscribe
China104042617► Subscribe
China106822080► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Healthtrust
Mallinckrodt
Baxter
Federal Trade Commission
Dow
Chinese Patent Office
Merck
Moodys
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot